Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 675 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Fatty Liver Disease Clear all

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: CT imaging; Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: Chandler, Arizona • Tucson, Arizona • Los Angeles, California + 13 more

Conditions: Cholestasis, Short Bowel Syndrome
Interventions: Omegaven; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Weight loss surgery; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Alcoholic Steatohepatitis
Interventions: SHP626, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 49
States / cities: Coronado, California • Fresno, California • Los Angeles, California + 42 more

Conditions: End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions: Tocotrienol (TCT), Placebo; Drug · Other
Lead sponsor: Chandan Sen; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 79 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Liver Diseases
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: NAFLD, Fatty Liver, Obesity, Metabolic Syndrome
Interventions: Diet Intervention; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 11 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more

Conditions: MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: MR exam, US exam, Blood draw, Physical measurements, Questionnaires; Diagnostic Test · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 9 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
Interventions: GE ultrasound system with increased acoustic output settings; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Fish Oil Supplementation, Placebo Supplementation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: intravenous fructose challenge, Blood Draw; Drug · Other
Lead sponsor: Manal F Abdelmalek; Other
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Gestational Diabetes Mellitus in Pregnancy
Interventions: Subjects with Gestational Diabetes, Controls without Gestational Diabetes; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Resmetirom; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more

Conditions: Hepatitis
Interventions: Metformin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions: AZ compound, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 75 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Non-Alcoholic Steatohepatitis
Interventions: BMS-986036, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Fatty Liver
Interventions: Metformin, Vitamin E, Matching placebo; Drug · Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Tropifexor (LJN452), Cenicriviroc (CVC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more

Conditions: Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions: Placebo, Silymarin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Fatty Liver, Insulin Resistance
Interventions: rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease

Liver Health and Metabolic Function in People With Obesity

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

Tocotrienol Against the Progression of End Stage Liver Disease

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)

Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

The Effect of Time-restricted Eating on Liver Metabolism

Conditionally Increased Output (CIO) Enhanced Ultrasound System

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease

The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Phase I Trial of Silymarin for Chronic Liver Diseases

Insulin Resistance in Non-alcoholic Fatty Liver Disease